Israel Active

Israel’s Bio-Technology General (BTG) develops therapies for reproductive health, endocrinology (growth hormones), orthopedic (knee lubricant), ophthalmology and arthritic pain relief. BTG has just inaugurated a new production line to enable expansion at its Be’er Tuvia site.

Three of Israel’s top brain scientists from Ben Gurion University of the Negev will be presenting at a symposium in New York City on Sun 27th Oct. Their subjects - Processing Face Recognition, Combating Autism and Treating Head Trauma. Tickets just $18.

I reported previously on the interatrial shunt developed by Israel’s V-Wave. The US FDA has just granted two Breakthrough Device Designations to the device - the first is for Heart Failure (HF), and the second, for Pulmonary Arterial Hypertension (PAH).

The infusion systems of Israel’s Eitan Medical (, and ), are installed worldwide. E.g. there are 100,000 of Q-cores Sapphire devices in the market. Eitan has now agreed that Canadian Hospital Specialties will supply and support Sapphire across Canada.

Israeli biotech Wize Pharma markets Israeli-developed LO2A eye drops for the treatment of ophthalmic disorders, including Dry Eye Syndrome. Wize is now to develop and trial the WP-REP1 gene therapy from Cleveland’s Copernicus for treating the rare eye disease Choroideremia.

Israeli startup Filterlex Medical has received 2.1 million euros from the European Union’s Horizon 2020 research and innovation program. Filterlex develops an embolic protection device to reduce the risk of stroke and other complications during catheter-based heart procedures.

I reported previously on Israel’s Body Vision Medical when it was producing hi-res maps of the lungs to aid tumor removal. Since then it has developed LungVision - a disposable lung navigation catheter which recently received US FDA approval. The company has also raised $20 million.

I recently reported that Israel’s SofWave had received CE certification for its non-invasive ultrasound technology for skin tightening. It has now also received FDA approval. 86% of a recent trial demonstrated improvement in wrinkle appearance.

I’ve reported previously on Israel’s Healthy.io and its smartphone-based urinalysis for Chronic Kidney Disease. It is now US and EU approved and some 100,000 kits have been sold. Healthy.io has just raised $60 million of funds. (UK Financial Times video)

I’ve reported previously on the diabetes monitors from Israel’s DreaMed. The US FDA has just given approval to DreaMed’s Advisor Pro, to add to its EU approval. The software tells Type 1 diabetics how much insulin to use, without having to contact a physician.